U.S. Intravenous Solution Market Size, Share & Forecast 2026–2032

ID: MR-11732 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Intravenous Solution Market
  • ✓Market Size 2024: USD 5.8 billion
  • ✓Market Size 2032: USD 8.7 billion
  • ✓CAGR: 5.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Single-Plant Concentration Risk: Baxter's North Cove, North Carolina plant, damaged by Hurricane Helene in September 2024, supplied a dominant share of U.S. saline and dextrose bags. Hospitals with dual-sourced contracts with B. Braun Medical restored supply faster.
FINDING 02
Reshoring Will Lag Tariffs: Contrary to the view that tariff-driven reshoring will quickly secure supply, new sterile fluid lines take years to win FDA approval. The Section 232 pharmaceutical import investigation will raise imported resin and container costs before domestic capacity arrives.
ANALYST RECOMMENDATION

Analyst Recommendation — Dual-Source Contracts Before Q2 2026: Hospital pharmacy directors and purchasing organizations should secure contracts with at least two sterile fluid manufacturers, with one source outside North Cove, before the second quarter of 2026. Section 506C notices and Helene-era backlogs mean interruptions will recur before 2027.

U.S. Intravenous Solutions: Market Overview

The U.S. intravenous solutions market, covering sodium chloride, dextrose, lactated Ringer's and sterile water supplied in large-volume flexible containers, was valued at USD 5.8 billion in 2024 and is forecast to reach USD 8.7 billion by 2032. Demand is anchored in hospital inpatient care, where IV fluids serve as the standard vehicle for resuscitation, electrolyte correction and drug delivery. The market is structurally concentrated, with Baxter International, B. Braun Medical and ICU Medical controlling the majority of large-volume parenteral output.

Policy has determined this structure in two ways. The Federal Food, Drug, and Cosmetic Act classifies large-volume parenterals as drugs, so FDA approval and current good manufacturing practice requirements keep entry barriers high and production concentrated. Government has been the dominant force on supply security through the Strategic National Stockpile administered by the Administration for Strategic Preparedness and Response, while private manufacturers have led product innovation, including premixed, phthalate-free and latex-free containers.

Policy-Driven Growth in U.S. Intravenous Solutions

Three policy mechanisms are driving demand and reshaping spend. First, Section 506C of the Federal Food, Drug, and Cosmetic Act, added by the Food and Drug Administration Safety and Innovation Act (Public Law 112-144, 2012), requires manufacturers to notify FDA at least six months before discontinuing or interrupting a drug. Hospitals respond by holding larger safety stocks and qualifying second sources, which lifts purchased volumes per bed. The notice regime turns shortage risk into a standing inventory cost that hospital pharmacy budgets now fund as a fixed line.

Second, the Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act, Public Law 113-54) mandates electronic, interoperable product tracing and lot-level traceability, with dispenser obligations for hospitals phased in through November 2024 and small dispensers through November 2025. Compliance software and tracing data costs push purchasing toward large distributors that can absorb them. Third, the Hospital Preparedness Program, administered by ASPR with annual funding of roughly USD 240 million, finances regional surge capacity, creating incremental demand for stockpiled crystalloid fluids in designated health care coalitions.

Regulatory Barriers and Compliance Costs

The first barrier is FDA drug approval. Each sterile fluid product requires an approved New Drug Application or Abbreviated New Drug Application under 21 U.S.C. 355, and the Office of Pharmaceutical Quality reviews facilities against 21 CFR Parts 210 and 211. PDUFA performance goals set a ten-month standard review for non-new molecular entity applications, but a new large-volume line adds substantial validation and inspection time, and the capital outlay for a single plant runs into the hundreds of millions of dollars.

The second barrier is tariffs and import controls. The Section 232 pharmaceutical investigation opened by the Department of Commerce in April 2025 threatens duties on imported finished drugs and active ingredients, and U.S. Customs and Border Protection applies those duties at entry. The third barrier is environmental. Manufacturing wastewater discharges require National Pollutant Discharge Elimination System permits issued by state agencies under the Clean Water Act, and EPA's Resource Conservation and Recovery Act rules govern hazardous waste from sterilization operations.

Policy-Created Opportunities in the U.S.

Strategic National Stockpile procurement creates a federally funded demand channel. ASPR's Strategic National Stockpile, authorized under Section 319F-2 of the Public Health Service Act, procures IV fluids and administration sets through competitive contracts, and manufacturers with FDA-registered domestic plants are positioned for federal volume commitments. Suppliers offering domestic fill-finish capacity and DSCSA-compliant transaction data are best placed to win these awards.

Home infusion is the second opportunity. Medicare Part B covers professional home infusion therapy services under the Bipartisan Budget Act of 2018, effective January 2021, and reimburses qualifying visits under HCPCS codes G0068 through G0070, which makes home-based IV therapy economically viable for accredited providers. Home infusion pharmacies accredited by The Joint Commission or the Accreditation Commission for Health Care can capture volume that shifts out of hospitals, while providers with established tracing systems are best placed for the November 2025 small-dispenser deadline.

Market at a Glance

MetricDetail
Market Size 2024USD 5.8 billion
Market Size 2032USD 8.7 billion
Growth Rate (CAGR)5.2%
Most Critical Decision FactorSupply redundancy and FDA-compliant manufacturing capacity
Largest RegionSouthern United States
Competitive StructureConsolidated, led by three multinational manufacturers

Leading Market Participants

  • Baxter International
  • B. Braun Medical
  • ICU Medical
  • Fresenius Kabi
  • Pfizer (Hospira)
  • Grifols
  • Otsuka America Pharmaceutical
  • Hikma Pharmaceuticals
  • Sagent Pharmaceuticals
  • Medline Industries

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by the Food and Drug Administration, which sets approval, labeling and current good manufacturing practice obligations for every IV solution. Section 506C, introduced through the Food and Drug Administration Safety and Innovation Act (Public Law 112-144), requires six-month advance notice of discontinuance or interruption. The Drug Supply Chain Security Act (Public Law 113-54) requires transaction history, transaction information and transaction statements, with hospitals as dispensers facing full electronic interoperability by November 2024 and small dispensers by November 2025.

Upcoming changes include the Section 232 pharmaceutical tariff decision, which will set duties on imported finished drugs and ingredients, and FDA's PreCheck program for new U.S. plants. Compared with regional peers, the U.S. framework is more permissive on importation but less coordinated on supply security. The European Union relies on the Falsified Medicines Directive (Directive 2011/62/EU) for traceability, and the European Commission proposed a Critical Medicines Act in March 2025 to mandate strategic stockpiling and supply diversification, whereas the U.S. relies largely on voluntary stockpiles and notice rules.

Long-Term Policy Outlook for U.S. Intravenous Solutions

By 2032, the U.S. market will be shaped by domestic onshoring. Section 232 duties and FDA's PreCheck facilitation will attract new sterile fluid lines, with capacity additions in the Southeast and Midwest reducing reliance on single-site output. Full DSCSA enforcement across dispensers will consolidate purchasing toward distributors able to run serialized data exchange, and group purchasing contracts will require documented second-source qualification.

Demand-side policy will also shift. Medicare Part B home infusion coverage will widen, supporting home-based crystalloid use, while Centers for Medicare & Medicaid Services inpatient payment rules keep hospital margins tight and push purchasers toward lower-cost, bulk-verified supply. EPA's Toxic Substances Control Act risk evaluations of phthalates will accelerate substitution toward polyolefin containers, reshaping resin supply chains before the end of the forecast period.

Frequently Asked Questions

The Food and Drug Administration approves IV solutions as drugs under the Federal Food, Drug, and Cosmetic Act, through New Drug Application or Abbreviated New Drug Application pathways. Each manufacturing site must also pass current good manufacturing practice inspections under 21 CFR Parts 210 and 211.
Under Section 506C, manufacturers must notify FDA at least six months before a permanent discontinuance or interruption likely to cause a shortage. Failure to provide notice exposes manufacturers to enforcement action.
Hospitals are classed as dispensers under DSCSA and must verify product identifiers and maintain transaction records. Small dispensers face the final electronic interoperability deadline in November 2025.
FDA's temporary importation policy allows foreign-sourced IV products during declared shortages, as used after Hurricane Helene in 2024. Importers must still meet labeling requirements and notify FDA before distribution.
Medicare Part B covers professional home infusion therapy services under HCPCS codes G0068 through G0070, established by the Bipartisan Budget Act of 2018. Providers must be enrolled in Medicare and meet the program's qualifying supplier requirements.

Market Segmentation

By Solution Type
  • Sodium Chloride Injection
  • Dextrose Injection
  • Lactated Ringer's Injection
  • Balanced Crystalloid Solutions
  • Sterile Water for Injection
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Home Infusion Providers
  • Dialysis Centers
  • Long-Term Care Facilities

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Intravenous Solutions - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Solution Type Insights
4.1 Sodium Chloride Injection
4.2 Dextrose Injection
4.3 Lactated Ringer's Injection
4.4 Balanced Crystalloid Solutions
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Home Infusion Providers
5.4 Dialysis Centers
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.1.1 Baxter International
6.1.2 B. Braun Medical
6.1.3 ICU Medical
6.1.4 Fresenius Kabi
6.1.5 Pfizer (Hospira)
6.2 Leading Market Participants
6.2.1 Baxter International
6.2.2 B. Braun Medical
6.2.3 ICU Medical
6.2.4 Fresenius Kabi
6.2.5 Pfizer (Hospira)
6.2.6 Grifols
6.2.7 Otsuka America Pharmaceutical
6.2.8 Hikma Pharmaceuticals
6.2.9 Sagent Pharmaceuticals
6.2.10 Medline Industries
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.